NDAORALCAPSULEPriority Review
Approved
Jan 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
Priority Review
EULEXIN (flutamide) by Merck & Co. is clinical pharmacology general in animal studies, flutamide demonstrates potent antiandrogenic effects. Approved for prostate cancer. First approved in 1989.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EULEXIN (flutamide) is an oral nonsteroidal androgen receptor antagonist approved in 1989 for prostate cancer, where it blocks androgen uptake and nuclear binding in target tissues. It is also used off-label for polycystic ovary syndrome and sexual dysfunction/infertility by counteracting androgenic effects.
$0.156MPart D
LOE ApproachingDeclining
Declining market presence with minimal Part D spending ($156K, 34 claims in 2023) signals a shrinking patient base and contracting team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY General In animal studies, flutamide demonstrates potent antiandrogenic effects. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive…
Worked on EULEXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.